Orion Corp
KRX:271560

Watchlist Manager
Orion Corp Logo
Orion Corp
KRX:271560
Watchlist
Price: 104 800 KRW -0.47% Market Closed
Market Cap: 4.1T KRW
Have any thoughts about
Orion Corp?
Write Note

Orion Corp
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Orion Corp
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Orion Corp
KRX:271560
Cash & Cash Equivalents
â‚©365.8B
CAGR 3-Years
-12%
CAGR 5-Years
20%
CAGR 10-Years
N/A
CJ CheilJedang Corp
KRX:097950
Cash & Cash Equivalents
â‚©1.5T
CAGR 3-Years
8%
CAGR 5-Years
21%
CAGR 10-Years
10%
Ottogi Corp
KRX:007310
Cash & Cash Equivalents
â‚©400.1B
CAGR 3-Years
60%
CAGR 5-Years
27%
CAGR 10-Years
16%
S
Samyang Foods Co Ltd
KRX:003230
Cash & Cash Equivalents
â‚©218.7B
CAGR 3-Years
34%
CAGR 5-Years
24%
CAGR 10-Years
27%
Dongwon Industries Co Ltd
KRX:006040
Cash & Cash Equivalents
â‚©637.9B
CAGR 3-Years
35%
CAGR 5-Years
39%
CAGR 10-Years
32%
Nongshim Co Ltd
KRX:004370
Cash & Cash Equivalents
â‚©142.9B
CAGR 3-Years
-19%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
No Stocks Found

Orion Corp
Glance View

Market Cap
4.1T KRW
Industry
Food Products

Perched within the competitive landscape of pharmaceuticals, Orion Corporation has steadily carved its niche since its inception in Finland in 1917. Starting as a small-scale factory operation, Orion has evolved into a pivotal player in the healthcare sector, blending traditional expertise with cutting-edge innovations. The company's core operations pivot around the development, manufacturing, and marketing of human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients (APIs). This dual focus allows Orion not only to reach a diverse market but also ensures a consistent revenue stream, supplemented by its strategic interest in self-care products. The company thrives on its robust research and development arm, constantly seeking innovations in therapeutic areas like central nervous system disorders, oncology, and respiratory diseases. Orion's financial engine hums efficiently through its vertically integrated business model. By managing most of the value chain internally—from drug discovery to production and distribution—Orion secures cost advantages and quality control, translating into a competitive edge in global markets. While Europe remains Orion's stronghold, it strategically seeks growth in regional markets, leveraging partnerships and alliances with international pharmaceutical giants to expand its footprint. This strategy not only augments its own pipeline with licensed products but also fortifies its market position, making it a sustainable player in an industry driven by constant change and regulated rigorously. The corporation's revenue streams thus embody a careful balance of organic product development and strategic collaborations, evidencing a business acumen grounded in long-term vision.

Intrinsic Value
153 695.88 KRW
Undervaluation 32%
Intrinsic Value
Price

See Also

What is Orion Corp's Cash & Cash Equivalents?
Cash & Cash Equivalents
365.8B KRW

Based on the financial report for Sep 30, 2024, Orion Corp's Cash & Cash Equivalents amounts to 365.8B KRW.

What is Orion Corp's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
20%

Over the last year, the Cash & Cash Equivalents growth was -9%. The average annual Cash & Cash Equivalents growth rates for Orion Corp have been -12% over the past three years , 20% over the past five years .

Back to Top